Selective serotonin reuptake inhibitor

Intermountain Healthcare Researchers Find Most Commonly Prescribed Class of Anti-Depressant Medications Do Not Reduce COVID Severity

Retrieved on: 
Wednesday, November 9, 2022
GLOBE, Hospital, Health, Doctor of Philosophy, American Heart, Research, Risk, Selective serotonin reuptake inhibitor, Death, COVID, Survival, Intermountain Healthcare, Patient, Physician, Lake City, SSRI, COVID-19, Pharmaceutical industry, Intermountain

In the early days of the COVID pandemic, some observational studies suggested there may be a link between greater survival and lower COVID severity in patients taking selective serotonin reuptake inhibitors (SSRIs) the most commonly prescribed class of antidepressants in America.

Key Points: 
  • In the early days of the COVID pandemic, some observational studies suggested there may be a link between greater survival and lower COVID severity in patients taking selective serotonin reuptake inhibitors (SSRIs) the most commonly prescribed class of antidepressants in America.
  • Its not surprising that early on researchers thought there might be a connection.
  • However, new research from Intermountain Healthcare finds that is not the case for people who test positive for COVID in an outpatient setting.
  • In this retrospective study, Intermountain researchers examined 33,088 people who tested positive for COVID-19 between March 14, 2020 - December 31, 2021, in an Intermountain outpatient setting.

Ascension Healthcare to Present Positive Phase 2 Data on Two Haemophilia Programmes at the 64th American Society of Hematology Annual Meeting

Retrieved on: 
Thursday, November 3, 2022
Fibrinolysis, University College London, Company, Male, 2021 Essex County Council election, Society, Ascension, Bleeding, ASH, Coronavirus Scientific Advisory Board (Turkey), Use, Potency, VIII, XLR8, Haemophilia, Risk, Prevalence, Selective serotonin reuptake inhibitor, Patient, Osteoarthritis, Pharmaceutical industry, Dentistry

The ASH annual meeting will take place from the10-13 December 2022 in New Orleans, Louisiana and virtually.

Key Points: 
  • The ASH annual meeting will take place from the10-13 December 2022 in New Orleans, Louisiana and virtually.
  • Biresh Roy, Chief Executive Officer at Ascension commented: We are immensely privileged to have been selected to present our successful Phase 2 SelectAte and XLR8 programmes at ASH, a world leader insupporting and promulgating clinical and scientific developments in haematology.
  • This is a large market that is, at present, not served by a safe, convenient, inexpensive prophylactic replacement FVIII treatment.
  • XLR8 is a form of PEGLip administered as an adjuvant to patients who already have some circulating FVIII.

Antidepressant Tapering Platform Outro Launches in Canada Ahead of World Tapering Day

Retrieved on: 
Tuesday, November 1, 2022
Technology, Mental Health, Health Technology, Software, Health, Pharmaceutical, General Health, Other Science, Science, Awareness, Dizziness, Sertraline, Grammatical mood, Psychotherapy, Citalopram, Method, Serotonin–norepinephrine reuptake inhibitor, Risk, COVID-19, Paroxetine, Headache, Technology, Anxiety, Selective serotonin reuptake inhibitor, Patient, Fluoxetine, Depression, Pharmaceutical industry, Online shopping, Facebook, Outro, Instagram

Outro , the first-of-its-kind platform harnessing technology and specialized care to help people reduce or stop the use of antidepressants, announces its launch in Canada ahead of World Tapering Day on November 5.

Key Points: 
  • Outro , the first-of-its-kind platform harnessing technology and specialized care to help people reduce or stop the use of antidepressants, announces its launch in Canada ahead of World Tapering Day on November 5.
  • Outros user-friendly platform provides science-based, personalized tapering plans to slowly reduce medication dosage.
  • We are incredibly excited to bring this platform to many in need across Canada, said Brandon Goode, co-founder and chief executive officer of Outro.
  • Outro is poised to help many in Canada and eventually more around the world.

Indiana Center for Recovery Unveils SPRAVATO® Ketamine Therapy for PTSD and Depression

Retrieved on: 
Monday, October 31, 2022
Safety, View, Multimedia, Patient, Chronic pain, Depression, Veteran, Stroke recovery, Selective serotonin reuptake inhibitor, Drug, Recovery, FDA, Hoosier, Substance abuse, MDD, PTSD, Pharmaceutical industry

BLOOMINGTON, Ind., Oct. 31, 2022 /PRNewswire/ -- Indiana Center for Recovery has added ketamine therapy to its award-winning services for Hoosiers and their families, making recovery more accessible for those with treatment-resistant conditions.

Key Points: 
  • BLOOMINGTON, Ind., Oct. 31, 2022 /PRNewswire/ -- Indiana Center for Recovery has added ketamine therapy to its award-winning services for Hoosiers and their families, making recovery more accessible for those with treatment-resistant conditions.
  • Adding ketamine therapy opens options for patients and possibilities for recovery," said Jackie Daniels, Director of Clinical Development,.
  • New patients will see how Indiana Center for Recovery's experts and professionals relieve depression, PTSD, and more through effective ketamine therapies that require only a few, short sessions.
  • About Indiana Center for Recovery Since 2016, Indiana Center For Recovery has pushed patient outcomes through expert staff, high-end facilities, and scientifically sound protocols for patient-centered recovery.

Small Pharma Reports Fiscal Second Quarter 2023 Highlights

Retrieved on: 
Friday, October 14, 2022
Selective serotonin reuptake inhibitor, Medicines and Healthcare products Regulatory Agency, Loss, MHRA, DMT, European College of Neuropsychopharmacology, MDD, Patient, First United States Army, Intellectual property, Composition of matter, Biotechnology, Depression, IV, GBP, Foreign, Commonwealth and Development Office, SSRI, Data, Company, Pharmacokinetics, IP, CTA, Patent, Safety, Genta (company), Psilocybin, GLOBE, 5-MeO-DMT, SEDAR, Pharmaceutical industry, Online gambling, Phase

LONDON, Oct. 14, 2022 (GLOBE NEWSWIRE) -- Small Pharma Inc. (TSXV: DMT) (OTCQB: DMTTF) (the “Company” or “Small Pharma”), a biotechnology company focused on short-acting psychedelic-assisted therapies for mental health conditions, has today published its financial results for the three and six months ended August 31, 2022. A full copy of the financial results can be found under the Company’s profile on SEDAR at www.sedar.com. Unless otherwise indicated, all currency references are in Canadian dollars.

Key Points: 
  • The trial requires patient follow-up for 12 weeks following their second dose, which is on track to be completed by the end of 2022.
  • Small Pharma is a biotechnology company progressing a pipeline of short-acting psychedelic assisted therapies for the treatment of mental health conditions.
  • Small Pharmas lead candidate, SPL026, is a proprietary synthetic formulation of DMT.
  • In addition, Small Pharma has a pipeline of proprietary preclinical assets in development.

Global Depression Treatment Therapy Market Research and Forecast Report 2022-2028 Featuring Key Players - Eli Lilly and Co., Johnson & Johnson, Pfizer, Merck, H. Lundbeck, & F. Hoffmann-La Roche - ResearchAndMarkets.com

Retrieved on: 
Thursday, October 13, 2022
Pharmaceutical, Health, Mental Health, Statistics, Suicide, Cyclothymia, Crime, Prevalence, Pfizer, Growth, Population, Tablet, CAGR, MDD, Johnson & Johnson, Depression, Merck & Co., Lists of diseases, Panic disorder, Geography, SSRI, Workload, Xanthine oxidase inhibitor, Serotonin, R, WHO, World, Lupinus, Selective serotonin reuptake inhibitor, Awareness, Obsessive–compulsive disorder, World Health Organization, Anxiety disorder, Sexual abuse, Femicide, Bulimia nervosa, Major depressive disorder, Eli Lilly and Company, OCD, Pharmaceutical industry, Oil, Anxiety

The "Global Depression Treatment Therapy Market Research and Forecast, 2022-2028" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Global Depression Treatment Therapy Market Research and Forecast, 2022-2028" report has been added to ResearchAndMarkets.com's offering.
  • The global depression treatment market is anticipated to grow at a considerable CAGR of 4.1% during the forecast period of 2020-2027.
  • The rising prevalence of depression among the global population is the major factor driving the growth of the depression treatment market.
  • The global depression treatment market is analyzed on the basis of the geographical regions that are contributing significantly towards the growth of the market.

Scientists Create Non-Psychedelic Compound with Same Anti-depressant Effect

Retrieved on: 
Wednesday, September 28, 2022
Mental Health, Research, Other Natural Resources, Other Health, Alternative Medicine, Health, Other Science, Science, Natural Resources, Tao, Selective serotonin reuptake inhibitor, National, Depression, Human, THP, LSD, DARPA, Patient, UNC, 5-HT2A, R-69, Anxiety, Research, Hallucination, Psychiatry, Eugene Higgins, Mouse, Serotonin, Doctor of Philosophy, DMT, Â, UCSF, Duke, Ketamine, Michael Hooker, FDA, MD, UNC School of Medicine, University of North Carolina at Chapel Hill, Stanford University, AstraZeneca, Permeability, Tony Hawk's Pro Skater 1 + 2, Department, Mount Sinai, Brain, Zehnder Confair, Psilocybin, Esketamine, Ellman, Neurochemistry, Defense, University of California, San Francisco, Protein, Cell, N,N-Dimethyltryptamine, Substance abuse, SSRI, Department of Defense Office of Inspector General, Multimedia, Neuron, Pharmaceutical industry, Yale University, Medicine, Pharmacology, Chemistry, Nature

Some advocates and scientists believe the actual psychedelic trip hallucinations and profound emotional experiences is what leads to long-lasting therapeutic effects.

Key Points: 
  • Some advocates and scientists believe the actual psychedelic trip hallucinations and profound emotional experiences is what leads to long-lasting therapeutic effects.
  • Other scientists speculate that if the trip could be eliminated from such drugs, then only the therapeutic effects might remain.
  • We were basically running a chemistry experiment to see if we could create a compound to activate 5-HT2A.
  • It would be a game changer to create a one-dose, long-acting therapy to help people with treatment-resistant depression and other conditions.

atai Life Sciences Announces Initiation of Phase 1 Trial for its MDMA Derivative, EMP-01

Retrieved on: 
Tuesday, September 27, 2022
Adult, Selective serotonin reuptake inhibitor, Therapy, PK, Safety, Amphetamine, Ethics, COVID-19, Infection, Brain, FDA, Addiction, Paroxetine, NEW, Norepinephrine, Senior, Intellectual property, MDMA, Private Securities Litigation Reform Act, HDEC, Hypertension, Stroke, Forward-looking statement, U.S. Securities and Exchange Commission, Public expenditure, Patient, Mental health, List of life sciences, CEO, Dopamine, Therapeutic index, Annual report, Nasdaq, Serotonin, Anxiety, Diagnosis, Cardiovascular disease, Pharmacology, Foundation for the National Institutes of Health, Research, Security (finance), GLOBE, Post-traumatic stress disorder, SEC, National Institute, Sertraline, PTSD, Failure, Depression, Pharmaceutical industry, Medsafe, Health

NEW YORK and BERLIN, Sept. 27, 2022 (GLOBE NEWSWIRE) -- atai Life Sciences N.V. (Nasdaq: ATAI) (“atai”), which is developing EMP-01, a 3,4-methylenedioxy-methamphetamine (MDMA) derivative for the treatment of post-traumatic stress disorder (PTSD) and other indications, announced today its Phase 1 study has received regulatory and ethics approvals required from Medsafe and HDEC, respectively, to initiate participant enrollment.

Key Points: 
  • Evidence shows that two-thirds of patients either do not respond or have only a partial response to these medications.
  • These modifications are designed to separate the entactogenic effects of MDMA from some of the known side effects, specifically its stimulant-associated effects.
  • Data on MDMA-assisted psychotherapy strongly suggests its potential for the treatment of PTSD, said Glenn Short, Senior Vice President, Early Development of atai Life Sciences.
  • atai Life Sciences is a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorders.

Freedom Biosciences Emerges from Stealth with $10.5 Million Seed Financing to Develop Next-Generation Ketamine and Psychedelic-based Mental Health Treatments

Retrieved on: 
Tuesday, August 23, 2022
Mental Health, Health, Clinical Trials, Research, Science, Pharmaceutical, Biotechnology, Psychedelic drug, MDMA, Research, Human, Division, NYSE, Psilocybin, View, Pfizer, Center for Drug Evaluation and Research, Program, Psychiatry, Hope, DMT, Department, Behavior, Ketamine, Depression, Coronavirus Scientific Advisory Board (Turkey), Center, Lists of diseases, FDA, Yale University, Therapy, History, Selective serotonin reuptake inhibitor, List of life sciences, Drug development, LSD, Imperial College London, Treatment-resistant depression, Patient, Pharmaceutical industry

Freedom Biosciences, a clinical-stage biotechnology platform developing next-generation viable and efficacious ketamine and psychedelic therapeutics, today emerged from stealth with $10.5 million in seed financing.

Key Points: 
  • Freedom Biosciences, a clinical-stage biotechnology platform developing next-generation viable and efficacious ketamine and psychedelic therapeutics, today emerged from stealth with $10.5 million in seed financing.
  • The new financing will help the company advance its current lead ketamine program as well as further multiple additional exploratory programs.
  • Burkitbayeva now serves as Freedom Biosciences CEO, while Dr. Krystal serves as its Chief Scientific Advisor.
  • Freedom Biosciences launched from stealth in 2022 and is backed by MBX Capital, Village Global and PsyMed Ventures, among others.

Indiana Center for Recovery Unveils BrainsWay Deep TMS™

Retrieved on: 
Tuesday, August 16, 2022
FDA, Multimedia, Mental health, Selective serotonin reuptake inhibitor, Technology, Lists of diseases, Deep, Patient, Company, TMS, Partnership, Tic disorder, Awareness, News, Brainsway, Goal, Mental, Eating recovery, Transcranial magnetic stimulation, Health, OCD, Pharmaceutical industry

SOUTH BEND, Ind., Aug. 16, 2022 /PRNewswire/ -- Indiana Center for Recovery—the largest mental health and addiction treatment provider in the state—announces its partnership with BrainsWay, a leader in noninvasive neurostimulation treatments for mental health disorders. This technology, combined with custom care plans from Indiana Center for Recovery, will bring recovery and relief through clinically demonstrated, painless treatments that can be highly effective when other treatment modes have failed.

Key Points: 
  • BrainsWay's Deep TMS treatment is based on novel breakthrough technology that targets brain areas for increased stimulation and activity.
  • Boosting care for patients with substance use and mental health disorders, Indiana Center for Recovery will use Deep TMS within holistic treatment paths unique to each patient.
  • New patients will see how Indiana Center for Recovery's experts and compassionate professionals use Deep TMS to promote true wellness in South Bend and beyond.
  • Since 2016, Indiana Center For Recovery has pushed patient outcomes through expert staff, high-end facilities, and scientifically sound protocols for patient-centered recovery.